Aadi Bioscience, Inc. announced partnerships with prominent next generation sequencing (NGS) providers and leaders in genomic testing and profiling, including Foundation Medicine, Tempus and others. They expect these collaborations to expedite patient identification for the ongoing PRECISION 1 trial of nab-sirolimus in patients harboring tumors with inactivating alterations in TSC1 or TSC2 genes. These partners will collect and analyze clinical and molecular data to determine which patients may be eligible to participate in Aadi's PRECISION 1 clinical trial.

The goals are to increase patient match rate, reduce screen failure rate and increase speed of enrollment into the trial.